Inflarx shares jump on new analysis of skin disease drug trial

Inflarx NV

19/07/2019 12:08

** U.S.-listed shares of Inflarx NV  IFRX.O  up 13% at $3.55
premarket 
    ** Co after hours on Thursday reports data from a new
analysis of its mid-stage study testing skin treatment, IFX-1
    ** Co says analysis suggests a "robust anti-inflammatory
activity" in a group of patients given the high dose of IFX-1
    ** In June, shares of Inflarx plunged after it reported
failure of the trial  urn:newsml:reuters.com:*:nL4N23D2GT
    ** Based on the additional analysis co says it plans to
continue to develop IFX-1 to treat hidradenitis suppurativa, a
painful, inflammatory skin disease  urn:newsml:reuters.com:*:nGNX3yC1Xy
    ** Up to Thursday's close, stock had fallen 91.4% YTD

 (Reporting by Tamara Mathias in Bengaluru)
 ((Tamara.Mathias@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 1208; Reuters Messaging:
tamara.mathias.thomsonreuters.com@reuters.net))